What Is Semaglutide? A Complete Peptide Guide

Semaglutide is a synthetic analog of human GLP-1 (glucagon-like peptide-1), a naturally occurring incretin hormone produced in the gut in response to food intake. Developed by Novo Nordisk, semaglutide was first approved by the FDA in 2017 for type 2 diabetes (as Ozempic®) and subsequently in 2021 for chronic weight management (as Wegovy®).

What makes semaglutide unique among GLP-1 analogs is its extended half-life of approximately 7 days — achieved through structural modifications including a fatty acid side chain that enables albumin binding and resistance to DPP-4 enzymatic degradation. This allows once-weekly dosing, a significant advantage over earlier GLP-1 drugs that required daily injection.

Semaglutide represents a paradigm shift in obesity treatment, with clinical trials showing it to be the most effective anti-obesity medication ever studied, surpassing all previous pharmacological interventions for weight loss.

Semaglutide exerts its effects through multiple pathways by activating GLP-1 receptors throughout the body:

• Appetite Suppression: GLP-1 receptors in the hypothalamus and brainstem regulate hunger and satiety. Semaglutide reduces appetite by enhancing satiety signals, making it easier to eat less without constant hunger.
• Gastric Emptying: Semaglutide slows the rate at which food leaves the stomach, prolonging the feeling of fullness after meals.
• Insulin Secretion: It stimulates glucose-dependent insulin release from pancreatic beta cells, meaning it enhances insulin secretion only when blood sugar is elevated — reducing the risk of hypoglycemia.
• Glucagon Suppression: Semaglutide reduces glucagon secretion, lowering hepatic glucose output and improving blood sugar control.
• Reward Pathways: Emerging research suggests GLP-1 agonists may modulate the brain's reward system, reducing cravings for high-calorie foods and potentially addictive behaviors.

Clinical trials have documented extensive benefits across multiple health domains:

• Weight Loss: The STEP trials demonstrated average weight loss of 14.9–16.9% of body weight at 68 weeks with semaglutide 2.4 mg weekly, with approximately one-third of participants losing over 20%.
• Blood Sugar Control: In the SUSTAIN trials, semaglutide achieved HbA1c reductions of 1.5–1.8% in type 2 diabetes patients.
• Cardiovascular Protection: The SELECT trial (2023) showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight/obese individuals without diabetes.
• Blood Pressure Reduction: Consistent systolic blood pressure reductions of 3–6 mmHg across trials.
• Liver Health: Emerging data from the ESSENCE trial shows significant benefit for metabolic dysfunction-associated steatohepatitis (MASH/NASH).
• Kidney Protection: The FLOW trial demonstrated significant renal protective benefits in patients with type 2 diabetes and chronic kidney disease.

Semaglutide dosing follows a gradual titration schedule to minimize gastrointestinal side effects:

• For weight management (Wegovy®): Start at 0.25 mg weekly for 4 weeks, then increase monthly through 0.5 mg, 1.0 mg, 1.7 mg, reaching the maintenance dose of 2.4 mg weekly.
• For type 2 diabetes (Ozempic®): Start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg, with optional increases to 1.0 mg or 2.0 mg based on glycemic response.
• Administration: Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Administer on the same day each week.
• Oral formulation (Rybelsus®): Available in 3 mg, 7 mg, and 14 mg tablets. Must be taken on an empty stomach with no more than 4 oz of water, at least 30 minutes before food or other medications.

Disclaimer: Semaglutide is a prescription medication. Dosing should be determined by your healthcare provider based on your specific medical condition and response to treatment.

Semaglutide's side effect profile is well-characterized through extensive clinical trials:

• Common (10–40%): Nausea, vomiting, diarrhea, constipation, and abdominal pain — typically most pronounced during dose escalation and often improving over time.
• Moderate: Headache, fatigue, dyspepsia, dizziness, and injection site reactions.
• Serious but rare: Pancreatitis, gallbladder disease (gallstones), and allergic reactions. In animal studies (but not confirmed in humans), thyroid C-cell tumors were observed, leading to a boxed warning.
• Muscle mass: Significant weight loss with semaglutide includes loss of lean mass (approximately 30–40% of weight lost may be lean tissue). Resistance training and adequate protein intake are recommended.

Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Not recommended during pregnancy or breastfeeding.

Semaglutide is available through multiple channels with different considerations:

• Prescription (brand name): Ozempic® and Wegovy® are available by prescription from licensed healthcare providers. Insurance coverage varies significantly.
• Compounding pharmacies: Due to ongoing shortages, compounded semaglutide is available from FDA-regulated 503B compounding pharmacies with a valid prescription.
• Research peptide suppliers: Semaglutide is available from peptide research suppliers for non-clinical use. Quality varies dramatically between vendors.

For research-grade semaglutide, we recommend Ascension Peptides. They provide comprehensive third-party COAs with HPLC purity testing and mass spectrometry verification, ensuring you receive an authentic, high-purity product. Their rigorous quality standards make them a standout in the peptide space.